L S Schneider


Affiliation: University of Southern California
Country: USA


  1. Schneider L, Dagerman K, Higgins J, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991-8 pubmed publisher
    ..Prospective trials are needed to further assess the potential for efficacy of memantine either alone or added to cholinesterase inhibitors in mild and moderate AD. ..
  2. Schneider L, Insel P, Weiner M. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58-66 pubmed publisher
    ..The use of these medications in ADNI is associated with clinical decline and may affect the interpretation of clinical trial outcomes. clinicalTrials.gov Identifier: NCT00106899. ..
  3. Schneider L. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn). 2013;19:339-57 pubmed publisher
    ..Marked advances in preclinical science nevertheless support a basis for considerable optimism that effective interventions will be found soon. ..
  4. Bang J, Lobach I, Lang A, Grossman M, Knopman D, Miller B, et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016;28:41-48 pubmed publisher
    ..Multiple clinical, neuropsychological, and volumetric MRI measurements are sensitive to change over one year in PSP and appropriate for use in multicenter clinical trials. ..
  5. Schneider L, Kennedy R, Wang G, Cutter G. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015;84:1121-7 pubmed publisher
    ..Until predictors of decline are better understood, considering effects of age on rates of change is particularly important regarding clinical practice and outcomes of trials. ..
  6. request reprint
    Schneider L. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med. 2001;17:337-58 pubmed
    ..This article reviews the present status of cholinesterase inhibitors for the treatment of Alzheimer's disease. It then discusses treatment approaches and current and future issues regarding efficacy and safety...
  7. request reprint
    Schneider L, Tariot P, Lyketsos C, Dagerman K, Davis K, Davis S, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001;9:346-60 pubmed
    ..They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented...
  8. request reprint
    Schneider L, Dagerman K, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210 pubmed
    ..Several clinical trials have not shown efficacy, and there have been concerns about adverse events. The objective of this study was to assess the evidence for efficacy and adverse events of atypicals for people with dementia...